Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192906 · ClinicalTrials.gov registry record · Phase 3
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
A Phase 3 study of Schizophrenia, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 624
- Enrollment target
- 20
- Study locations
NCT01192906: Completed Phase 3 study of Schizophrenia, sponsored by Hoffmann-La Roche.
NCT01192906 is a Phase 3 study of Schizophrenia that has completed, run by Hoffmann-La Roche. The registered enrollment target is 624 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01192906, a Phase 3 study of Schizophrenia, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 624 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG bitopertin [RO4917838]
Study Locations (20)
California
- - Carson
- - Oceanside
- - San Diego
- - San Diego
Illinois
- - Chicago
- - Hoffman Estates
- - Joliet
New York
- - Cedarhurst
- - Jamaica
- - Rochester
Connecticut
- - Hartford
- - Norwalk
Louisiana
- - Lake Charles
- - Shreveport
Pennsylvania
- - Allentown
- - Norristown
Florida
- - North Miami
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
What the finished NCT01192906 record still lists
NCT01192906 is an interventional study that assigns participants to a tested intervention. The registered 624 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (188% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01192906 names 20 study sites across 10 states, led by California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT01192906 about?
NCT01192906 is a clinical study titled "A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)". This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to ...
What is the current status of trial NCT01192906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2010-12. Estimated completion is 2014-07.
What conditions does trial NCT01192906 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01192906?
The interventions under investigation include: Placebo (DRUG), bitopertin [RO4917838] (DRUG).
Who is sponsoring clinical trial NCT01192906?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01192906 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01192906's enrollment target sits among peer trials
624 25th of 315 higher than 291 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia